CRANSWICK PLC financials
CRANSWICK PLC
Country: GB Reporting currency: GBP Latest annual report: 2025-03-29
LEI:
549300LDZLPU51XOSK43 Financial statements
(GBP, as reported — unscaled; 102 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | £2.72B | £2.60B |
| Depreciation & amortisation | £3.6M | £5.0M |
| Operating profit (EBIT) | £190.6M | £166.9M |
| Finance costs | £9.2M | £8.9M |
| Profit before tax | £181.6M | £158.4M |
| Income tax expense | £47.3M | £45.3M |
| Profit for the year | £134.3M | £113.1M |
| Total comprehensive income | £134.4M | £113.0M |
| Per share | ||
| Basic EPS | £2.50 | £2.10 |
| Diluted EPS | £2.46 | £2.10 |
| Free cash flow / share | £1.44 | £2.54 |
| Cash flow statement | ||
| Cash generated from operations | £257.8M | £269.8M |
| Net cash from operating activities | £216.3M | £228.4M |
| Net cash from investing activities | -£160.4M | -£123.3M |
| Purchase of PP&E (capex) | £137.6M | £91.4M |
| Net cash from financing activities | -£77.0M | -£98.4M |
| Dividends paid | £49.5M | £43.9M |
| Proceeds from borrowings | £18.0M | -£14.0M |
| Repayments of borrowings | £0 | £6.5M |
| Lease liability payments | £16.2M | £14.2M |
| Balance sheet | ||
| Total assets | £1.53B | £1.38B |
| Non-current assets | £944.4M | £832.3M |
| Property, plant & equipment | £605.4M | £518.9M |
| Right-of-use assets | £123.7M | £92.4M |
| Intangible assets & goodwill | £210.9M | £213.5M |
| Current assets | £586.8M | £551.7M |
| Inventories | £126.9M | £113.7M |
| Trade & other receivables | £355.0M | £325.3M |
| Cash & equivalents | £5.9M | £27.0M |
| Total equity | £987.9M | £911.5M |
| — attributable to owners | £987.9M | £911.5M |
| Non-current liabilities | £196.1M | £141.1M |
| Lease liabilities (non-current) | £116.3M | £82.1M |
| Current liabilities | £347.2M | £331.4M |
| Lease liabilities (current) | £16.4M | £17.3M |
| Trade & other payables | £328.1M | £310.0M |
| Deferred tax liabilities | £32.0M | £28.4M |
| Derived metrics | ||
| Free cash flow | £78.7M | £137.0M |
| Operating margin | 7.0% | 6.4% |
| Net margin | 4.9% | 4.4% |
| Return on equity | 13.6% | 12.4% |
| Cash conversion ratio | 1.61× | 2.02× |
| Capex coverage | 1.57× | 2.50× |
| Other reported items | ||
| Adjustments For Amortisation Expense | £3.6M | £5.0M |
| Adjustments For Decrease Increase In Biological Assets | -£8.7M | -£1.3M |
| Adjustments For Decrease Increase In Inventories | -£12.8M | £300.0K |
| Adjustments For Decrease Increase In Trade and Other Receivables | -£26.6M | -£33.8M |
| Adjustments For Finance Income Cost | -£9.2M | -£8.9M |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | -£900.0K | -£1.0M |
| Adjustments For Gains Losses On Change In Fair Value Less Costs To Sell Biological Assets | -£11.1M | £2.2M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | £1.6M | £15.4M |
| Adjustments For Income Tax Expense | £47.3M | £45.3M |
| Adjustments For Increase Decrease In Trade and Other Payables | £3.8M | £28.2M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | £0 | £200.0K |
| Adjustments For Sharebased Payments | £8.4M | £8.8M |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | £200.0K | £400.0K |
| Cash | £5.9M | £27.0M |
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | £200.0K | £0 |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | £25.0M | £23.5M |
| Current Biological Assets | £91.8M | £83.7M |
| Current Financial Assets | £300.0K | £0 |
| Current Financial Liabilities | £300.0K | £2.3M |
| Current Provisions | £2.4M | £1.8M |
| Current Tax Assets | £6.9M | £2.0M |
| Current Tax Relating To Items Charged Or Credited Directly To Equity | -£1.0M | -£500.0K |
| Deferred Tax Relating To Items Charged Or Credited Directly To Equity | -£2.7M | -£1.4M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | £0.25 | £0.23 |
| Dividends Recognised As Distributions To Owners Per Share | £0.76 | £0.67 |
| Gains Losses On Cash Flow Hedges Before Tax | £300.0K | -£100.0K |
| Gains Losses On Change In Fair Value Estimates of Biological Assets For Current Period | -£11.1M | £2.2M |
| Impairment Loss Impairment Gain and Reversal of Impairment Loss Determined In Accordance With IFRS9 | £1.6M | £15.4M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | £100.0K | -£100.0K |
| Income Tax Relating To Components of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | £0 | £0 |
| Income Taxes Paid Refund Classified As Operating Activities | £41.5M | £41.4M |
| Increase Decrease In Cash and Cash Equivalents | -£21.1M | £6.7M |
| Increase Decrease Through Exercise of Options | £4.7M | £4.4M |
| Increase Decrease Through Sharebased Payment Transactions | £8.4M | £8.8M |
| Interest Paid Classified As Financing Activities | £2.7M | £5.0M |
| Investments In Joint Ventures Accounted For Using Equity Method | £0 | £800.0K |
| Issued Capital | £5.4M | £5.4M |
| Liabilities | £543.3M | £472.5M |
| Net Assets Liabilities | £987.9M | £911.5M |
| Noncurrent Biological Assets | £4.3M | £6.4M |
| Noncurrent Financial Liabilities | £45.6M | £27.1M |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | £100.0K | £100.0K |
| Noncurrent Payables | £500.0K | £900.0K |
| Noncurrent Provisions | £1.7M | £2.6M |
| Noncurrent Recognised Assets Defined Benefit Plan | £0 | £200.0K |
| Other Comprehensive Income | £100.0K | -£100.0K |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | -£200.0K | £0 |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | £300.0K | -£100.0K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -£200.0K | £0 |
| Payments To Acquire Or Redeem Entitys Shares | £25.3M | £15.6M |
| Proceeds From Issuing Shares | £4.7M | £4.4M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | £2.0M | £800.0K |
| Purchase of Interests In Investments Accounted For Using Equity Method | £0 | £100.0K |
| Reclassification Adjustments On Cash Flow Hedges Before Tax | -£100.0K | £100.0K |
| Reserve of Cash Flow Hedges | £300.0K | -£100.0K |
| Reserve of Sharebased Payments | £14.2M | £11.8M |
| Retained Earnings | £870.4M | £781.7M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | £200.0K | £400.0K |
| Share Premium | £133.0M | £128.3M |
Methodology
Every line item above is a fact tagged in CRANSWICK PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (GBP), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.